Last reviewed · How we verify
premix insulin
Premix insulin is a combination of rapid-acting and intermediate-acting insulin that replaces or supplements the body's natural insulin to regulate blood glucose levels.
Premix insulin is a combination of rapid-acting and intermediate-acting insulin that replaces or supplements the body's natural insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | premix insulin |
|---|---|
| Also known as | human insulin or analog |
| Sponsor | Shanghai 6th People's Hospital |
| Drug class | Insulin combination product |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Premix insulin formulations contain a fixed ratio of short-acting (or rapid-acting) insulin and intermediate-acting insulin in a single injection. The rapid-acting component provides immediate postprandial glucose control, while the intermediate-acting component provides basal coverage. This combination mimics physiological insulin secretion patterns and is used to achieve glycemic control in patients with diabetes mellitus.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Comparative Efficacy of a Two Daily Mixed Insulin Injection Versus a Basal-bolus Scheme With Human Insulin (PHASE4)
- A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
- The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy (NA)
- A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
- Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (PHASE3)
- Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM (NA)
- Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (PHASE3)
- Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- premix insulin CI brief — competitive landscape report
- premix insulin updates RSS · CI watch RSS
- Shanghai 6th People's Hospital portfolio CI